GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Median PS Value
中文

Alkermes (Alkermes) Median PS Value

: $43.98 (As of Today)
View and export this data going back to 1991. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Alkermes's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $9.819. Alkermes's 10-Year median PS Ratio is 4.4791. Therefore, the Median PS Value for today is $43.98.

As of today (2024-04-24), Alkermes's share price is $24.53. Alkermes's Median PS Value is $43.98. Therefore, Alkermes's Price to Median PS Value for today is 0.56.

The historical rank and industry rank for Alkermes's Median PS Value or its related term are showing as below:

ALKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35   Med: 0.58   Max: 2.66
Current: 0.56

During the past 13 years, the highest Price to Median PS Value of Alkermes was 2.66. The lowest was 0.35. And the median was 0.58.

ALKS's Price-to-Median-PS-Value is ranked better than
75% of 500 companies
in the Drug Manufacturers industry
Industry Median: 0.79 vs ALKS: 0.56

Alkermes Median PS Value Historical Data

The historical data trend for Alkermes's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.87 47.47 48.43 46.44 43.98

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.44 45.88 54.94 48.27 43.98

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes Price-to-Median-PS-Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Alkermes's Price-to-Median-PS-Value falls into.



Alkermes Median PS Value Calculation

Alkermes's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=9.819*4.4791
=43.98

10-Year Median PS Ratio is 4.4791.
Alkermes's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.819.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alkermes  (NAS:ALKS) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Alkermes's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=24.53/43.98
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alkermes Median PS Value Related Terms

Thank you for viewing the detailed overview of Alkermes's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451